Literature DB >> 17826390

Predictors of survival in patients with end-stage renal disease evaluated for kidney transplantation.

Fadi G Hage1, Stuart Smalheiser, Gilbert J Zoghbi, Gilbert J Perry, Mark Deierhoi, David Warnock, Ami E Iskandrian, Angelo M de Mattos, Raed A Aqel.   

Abstract

Cardiovascular disease is the major cause of mortality in patients with end-stage renal disease (ESRD). This study examined the all-cause mortality in 3,698 patients with ESRD evaluated for kidney transplantation at our institution from 2001 to 2004. Mean age for the cohort was 48+/-12 years, and 42% were women. Stress myocardial perfusion imaging was done in 2,207 patients (60%) and coronary angiography in 260 patients (7%). There were 622 deaths (17%) during a mean follow-up period of 30+/-15 months. The presence and severity of coronary disease on angiography was not predictive of survival. Coronary revascularization did not impact survival (p=0.6) except in patients with 3-vessel disease (p=0.05). The best predictor of death was left ventricular ejection fraction, measured by gated myocardial perfusion imaging, with 2.7% mortality increase for each 1% ejection fraction decrease. In conclusion, left ventricular ejection fraction is a strong predictor of survival in patients with ESRD awaiting renal transplantation. Strategies to improve cardiac function or earlier renal transplantation deserve further studies.

Entities:  

Mesh:

Year:  2007        PMID: 17826390     DOI: 10.1016/j.amjcard.2007.04.045

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  27 in total

Review 1.  Atherosclerosis in CKD: differences from the general population.

Authors:  Tilman B Drüeke; Ziad A Massy
Journal:  Nat Rev Nephrol       Date:  2010-10-26       Impact factor: 28.314

Review 2.  Screening for cardiovascular disease before kidney transplantation.

Authors:  Sneha Palepu; G V Ramesh Prasad
Journal:  World J Transplant       Date:  2015-12-24

3.  The diagnostic accuracy of stress myocardial perfusion scintigraphy in patients with end-stage renal disease.

Authors:  Ahmed Fathala; Mohammed Alqattan; Riyadh Alsalloum
Journal:  Am J Cardiovasc Dis       Date:  2021-04-15

4.  The prognostic value of left ventricular mechanical dyssynchrony using gated myocardial perfusion imaging in patients with end-stage renal disease.

Authors:  Himanshu Aggarwal; Wael A AlJaroudi; Shikha Mehta; Roslyn Mannon; Jaekyeong Heo; Ami E Iskandrian; Fadi G Hage
Journal:  J Nucl Cardiol       Date:  2014-05-24       Impact factor: 5.952

5.  Prognostic value of myocardial perfusion imaging performed pre-renal transplantation: post-transplantation follow-up and outcomes.

Authors:  Christopher W Ives; Wael A AlJaroudi; Vineeta Kumar; Ayman Farag; Dana V Rizk; Suzanne Oparil; Ami E Iskandrian; Fadi G Hage
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-06-07       Impact factor: 9.236

Review 6.  Cardiovascular imaging in diabetes mellitus.

Authors:  Fadi G Hage; Ami E Iskandrian
Journal:  J Nucl Cardiol       Date:  2011-10       Impact factor: 5.952

7.  Use of regadenoson in end-stage renal disease.

Authors:  Ami E Iskandrian; Fadi G Hage; Jaekyeong Heo
Journal:  J Nucl Cardiol       Date:  2013-04       Impact factor: 5.952

8.  Screening for coronary artery disease in kidney transplant candidates.

Authors:  Dana V Rizk; Samy Riad; Fadi G Hage
Journal:  J Nucl Cardiol       Date:  2014-10-09       Impact factor: 5.952

Review 9.  Cardiac imaging for the assessment of patients being evaluated for kidney or liver transplantation.

Authors:  Kalindi Parikh; Andrew Appis; Rami Doukky
Journal:  J Nucl Cardiol       Date:  2014-10-08       Impact factor: 5.952

Review 10.  Cardiovascular risk assessment among potential kidney transplant candidates: approaches and controversies.

Authors:  Krista L Lentine; Frank P Hurst; Rahul M Jindal; Todd C Villines; Jeffrey S Kunz; Christina M Yuan; Paul J Hauptman; Kevin C Abbott
Journal:  Am J Kidney Dis       Date:  2009-09-23       Impact factor: 8.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.